admin

About admin

Medinol Site Webmaster

Posts by Webmaster :

2020 12 25

Schemes administered by Prime Cure

admin Uncategorized

Effective Jan 2017

Schemes Administered by Prime Cure

2020 12 24

Compcare 2017 Plan Changes

admin Uncategorized

Effective Jan 2017

CompCare 2017

2020 12 24

Medicine price increases capped for 2020

admin Uncategorized

Medicine price increases capped for 2020

Medicine price increases will be capped at 4.53% for 2020, according to reports.

The announcement was published in the government gazette last week,with health minister Dr Zweli Mkhize noting that that applications for adjustments of the single-exit price could be submitted for the first time from January 10 to no later than February 28.

Increases were capped at 3.78% in 2019.

The department determines the maximum price increase using a formula that factors in CPI, PPI as well as the exchange rate and international prices. It maintains tight control over medicine prices to ensure that companies do not pass margin strain onto consumers through higher prices.

Earlier in the year, the pricing committee said it would constantly review the formula used to determine the price caps, taking into account stakeholder feedback, but it would be consistent for at least the next three years (through to 2022).

Healthcare changes in South Africa

The price adjustments come amid a host of changes to South Africa’s healthcare landscape, with the introduction of the National Health Insurance being at the top of the pile.

Along with the NHI, medical aid schemes and private healthcare practitioners are preparing themselves for a shake-up in the industry.

Original article

Tags: 2020+medicine+price+increases

2020 12 23

Medshield Medical Scheme under provisional curatorship

admin Dental Practices, Latest News, Medical Aid, Medical Practices, Practice Management 0

From the Council for Medical Schemes:

Press release 17 of 2012: Medshield Medical Scheme under provisional curatorship

The North Gauteng High Court in Pretoria placed Medshield Medical Scheme under provisional curatorship today, following

the successful application of the Council for Medical Schemes to address governance concerns at the scheme.

Council is the regulator of the medical schemes industry, responsible for enforcing compliance with the Medical Schemes

Act 131 of 1998 to ensure that the interests of beneficiaries are prioritised at all times.

The provisional curator, Mr. Themba Langa, replaces the current Board of Trustees and Principal Officer and must ensure

that a new Board takes over the reigns at Medshield in due course, one that is fit and proper to run the affairs of the

scheme.

Assurance to beneficiaries

Beneficiaries of Medshield should rest assured that the claims-paying ability of their scheme is not affected by the

provisional curatorship.

Dr Monwabisi Gantsho, Registrar of Medical Schemes and Chief Executive of the Council said: “The provisional curatorship

has nothing to do with the financial soundness of the scheme. There are no concerns whatsoever over the financial position

of the scheme.”

Medshield remains one of the largest and healthiest schemes in the market. At the end of 2011, the scheme had over

236 000 beneficiaries and a solvency of 36.6% – which is above the 25.0% required by the Medical Schemes Act.

Medshield remains financially sound and sustainable in the long run. Dr Gantsho added: “I am looking forward to a speedy

return of the scheme to sound governance. The curator will be working very closely with the Regulator in this regard.”

Advice to brokers

Brokers are advised to act with restraint. Any advice they give must accord with the principles

2020 12 23

admin Uncategorized

IVERMECTIN IS NOT INDICATED NOR APPROVED BY SAHPRA FOR USE IN HUMANS

Ivermectin has made headlines recently as a so-called “miracle cure” for COVID-19. However, SAHPRA’s stance is unambiguous. This drug is not approved by SAHPRA and any attempt to import this drug into the country will be perceived as being unlawful.

Ivermectin is not indicated nor approved by SAHPRA for use in humans. There is no confirmatory data on Ivermectin available as yet for its use in the management of Covd-19 infections. In terms of safety and efficacy there is no evidence to support the use of ivermectin and we do not have any clinical trial evidence to justify its use.

At present, there is no confirmatory clinical evidence available for the use of Ivermectin in the management of Covd-19 infections.

SAHPRA is focused on quality, safety and efficacy and its ultimate goal is to protect the health and well being of all those who live in South Africa. The use of such a drug could potentially lead to harmful effects or even death and SAHPRA is firm on the stance that this medicine is unproven in the management of COVID-19 infections. Any attempt to import this drug will be dealt with by SAHPRA’s Regulatory Compliance unit in conjunction with law enforcement agencies such as SAPS and the SIU.

If you are aware of such transgressions, please contact Mr Deon Poovan, Senior Manager: Inspectorate and Regulatory Compliance on deon.poovan@sahpra.org.za

Read original article

Tags: IVERMECTIN+NOT+INDICATED+NOR+APPROVED

2020 12 23